Ashvattha Therapeutics develops hydroxyl dendrimer-based nanomedicines that selectively target activated cells in inflamed tissues, addressing unmet medical needs in ophthalmology, neurology, and inflammatory diseases. This precision approach enhances treatment efficacy by ensuring that therapeutics are delivered specifically to areas of inflammation, minimizing off-target effects.
Funding
$149.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many current treatments for ophthalmic, neurological, and inflammatory diseases lack precision, leading to off-target effects and reduced efficacy due to their inability to selectively target inflamed tissues. Effective drug delivery across biological barriers like the blood-retinal barrier and blood-brain barrier remains a significant challenge.
Solution
Ashvattha Therapeutics is developing a new class of nanomedicines based on hydroxyl dendrimer (HD) technology designed to selectively target activated cells within inflamed tissues. These precision nanomedicines traverse tissue barriers to deliver therapeutics directly to the site of inflammation, minimizing impact on healthy cells. This targeted approach aims to improve treatment outcomes in ophthalmology by targeting activated microglia, macrophages, and retinal pigment epithelial cells, in neurology by enabling quantitative study of blood-brain barrier penetration and treatment response, and in inflammatory diseases by modulating the activity of cells that drive inflammation.
Target Audience
The primary target audience includes patients with ophthalmic diseases, neurological disorders, and inflammatory conditions, as well as the physicians and specialists who treat these conditions.
Features
- Hydroxyl dendrimer (HD) technology for targeted drug delivery to inflamed tissues
- Selective uptake by activated cells, minimizing off-target effects
- Potential to cross the blood-retinal barrier for ophthalmic applications
- Development of a biomarker for neuroinflammation to study blood-brain barrier penetration
- CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) treatment
- Imaging agent 18F-OP-801 to target neuroinflammation in neurological indications